Description     Claims     Drawing  

US5962233A   [0054] 
US5925517A   [0054] 
AU2007000101W   [0089] 
WO07087684A   [0089]  [0092] 
WO02060872A   [0092] 
AU2014902541   [0193]  [0195] 

2013 discloses a phase I/II trial of BNC 105P with everolimus in metastatic renal cell carcinoma patients   [0003] 
2009 discloses identification of biomarkers of vascular disrupting agent activity during AVE8062 phase I trials in solid tumors   [0004] 
2013 discloses phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors   [0005] 
A Practical Guide to Molecular Cloning   [0028] 
Molecular Cloning: A Laboratory Manual   [0028] 
Protein Purification - Principals and Practice   [0028] 
Essential Molecular Biology: A Practical Approach   [0028] 
DNA Cloning: A Practical Approach   [0028] 
Current Protocols in Molecular Biology   [0028] 
Antibodies: A Laboratory Manual   [0028] 
Current Protocols in Immunology   [0028] 
Short Protocols in Molecular Biology   [0050] 
Molecular Cloning   [0050] 
Anticancer Drug Des.   [0095] 
Design of Prodrugs   [0095] 
The Practice of Medicinal Chemistry   [0095] 
A Textbook of Drug Design and Development   [0095] 
Nucleic Acids Res   [0194] 
J Biol Chem   [0194] 
Nat Rev Genet   [0194]